inhibikase.com (IKT) EV/EBITDA Multiple

Corporate company logo of Inhibikase Therapeutics (IKT)

Inhibikase Therapeutics (IKT) specializes in developing small-molecule agents against neurodegeneration, while the absence of commercialized products leaves the company dependent on external financing. High barriers to entry in the industry are driven by stringent capital and scientific requirements. The current EV/EBITDA ratio stands at 0.00. This price chart highlights the impact of patent disputes and Parkinson's disease drug trial results on the business valuation.

Inhibikase - IKT Total Company Value to Operating Income Before Depreciation Ratio (period 11/23/2025 - 11/16/2026)

Metric breakdowns and analytics for Inhibikase Therapeutics Inc (IKT)

- current price and projected stock value:
Comprehensive company analysis:Inhibikase Therapeutics Inc IKT
Product sample of Inhibikase Therapeutics, Inc.

For Inhibikase Therapeutics (IKT), which invests in the robotization of compound screening, the balance between asset costs and operational efficiency is critical. The company's EV/EBITDA ratio compares the total enterprise value, including debt, with earnings before interest, taxes, depreciation, and amortization. This chart reflects the extent to which the market overvalues the potential of drug development automation. Investors should interpret sharp spikes as a signal of shifting market expectations or the risk of overpayment.

Competitor analysis

Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Biogen Inc BIIB|EV/EBITDA Multiple neurocrine.com NBIX|RGC - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA Axsome|ACAD: EV/EBITDA Multiple|Enterprise Value to Operating Income Before Depreciation XENE|VKTX (Viking Therapeutics Corp) - EV/EBITDA Multiple|Enterprise Value to Operating Income Before Depreciation SUPN (Supernus)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Catalyst Pharma (CPRX)|DNLI (Denali Therapeutics Inc) - Business Value to Operating Income Before Depreciation|Harmony Pharma - Enterprise Value to EBITDA Ratio|BHVN: Enterprise Value to Operating Income Before Depreciation|Amylyx Pharmaceuticals - EV/EBITDA Multiple|Company Value to EBITDA trevitherapeutics.com|PRAX: EV/EBITDA Multiple|Company Value to Operating Income Before Depreciation Ratio AVXL (Anavex Life Sciences Corp.)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization CeriBell, Inc.|Company Value to EBITDA Prothena Biosciences PRTA|Enterprise Value to EBITDA Ratio ALEC (Alector Therapeutics)|Total Company Value to Operating Income Before Depreciation Ratio Annexon, Inc.|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Omeros Corporation OMER|NGNE - Enterprise Value to EBITDA Ratio|ACIU - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio VYGR|NMRA: EV/EBITDA Multiple|Scilex Holding Company - Business Value to Operating Income Before Depreciation|TVGN (Tevogen Bio Holdings, Inc.) - EV/EBITDA Multiple|EV/EBITDA Multiple Alpha Cognition|EV/EBITDA Multiple CGTX|SAVA (Cassava) - Business Value to Operating Income Before Depreciation|Assertio Holdings, Inc. - Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation COYA|VistaGen Therapeutics, Inc. - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio Ovid Therapeutics OVID|ABOS: EV/EBITDA Multiple|CervoMed Corporation (CRVO) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Alterity Therapeutics Limited|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization CLNN|EV/EBITDA Multiple PEPG|JUNS (Jupiter Neurosciences) - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Relmada Corp RLMD|EV/EBITDA Multiple Annovis Bio Corporation ANVS|gracetx.com - EV/EBITDA Multiple|Firefly Neuroscience, Inc (AIFF) - Enterprise Value to EBITDA Ratio|Klotho Neurosciences (KLTO) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|NeuroSense Therapeutics, Ltd. - Business Value to Operating Income Before Depreciation|RVPH (Reviva Pharmaceuticals Holdings) - EV/EBITDA Multiple|MetaVia Inc (MTVA) - Total Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple NRXS|Total Company Value to Operating Income Before Depreciation Ratio Helius Medical Technologies Inc.|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization passagebio.com PASG|NEUP: Enterprise Value to Operating Income Before Depreciation|NERV - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Athira - Enterprise Value to Operating Income Before Depreciation Ratio|ADXN: EV/EBITDA Multiple|ALZN (Alzamend Neuro, Inc.) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Cyclerion Therapeutics Inc.|PTIX: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple KTTA|Enterprise Value to Operating Income Before Depreciation Ratio CRGT|Avenue Therapeutics Inc - Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation BCLI|CARA - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Business Value to Operating Income Before Depreciation CHRO (Chromocell Therapeutics Corp)|ELYM: EV/EBITDA Multiple|Enterprise Value to Operating Income Before Depreciation ITCI|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Longboard Pharmaceuticals Inc|marinuspharma.com (MRNS) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to EBITDA Ratio NKGN (NKGen Biotech, Inc.)|NRBO - Company Value to EBITDA|EV/EBITDA Multiple SAGE (Sage Therapeutics, Inc)|SNPX: Enterprise Value to Operating Income Before Depreciation|Trevena Inc. - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio vigilneuro.com VIGL|WENA: EV/EBITDA Multiple|Company Value to EBITDA Cerevel Therapeutics Inc (CERE)